Novavax (NVAX) Up On Positive Influenza Study Results
Tweet
Share
E-mailGet Alerts NVAX Hot Sheet
Up)Join SI Premium – FREE
Novavax, Inc. (Nasdaq: NVAX) is en fuego this morning following positive results on a phase II human clinical trial of its trivalent seasonal influenza virus-like particle (VLP) vaccine candidate.
Shares are up 25% currently on heavy volume.
NVAX is one of the 'it' H1N1 (swine flu) stocks, along with BioCryst (Nasdaq: BCRX) and Vical (Nasdaq: VICL), Sinovac Biotech (NYSE: SVA).
Shares are up 25% currently on heavy volume.
NVAX is one of the 'it' H1N1 (swine flu) stocks, along with BioCryst (Nasdaq: BCRX) and Vical (Nasdaq: VICL), Sinovac Biotech (NYSE: SVA).
You May Also Be Interested In
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Unilever (UL) shares jump as sales growth accelerate in Q1
- Morgan Stanley issues a double upgrade on eBay while downgrading Etsy
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
